EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?

Slides:

Advertisements

Similar presentations

Date of download: 9/17/2016 Copyright © 2016 McGraw-Hill Education. All rights reserved. Schematic comparison of structural features of cell surface growth.

Advertisements

Volume 2, Issue 3, Pages (March 2015)

EGFR exon 20 insertion mutations

Defining Epidermal Growth Factor Receptor exon 20 mutant sensitivity to tyrosine kinase inhibition Danny Rayes.

Samsung Genome Institute Samsung Medical Center

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP CHEST

Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations Adi Gazdar, MD, Linda Robinson, MS, Dwight Oliver, MD,

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical.

Schematic comparison of structural features of cell surface growth factor receptor tyrosine kinases and membrane-associated tyrosine kinase oncogene products.

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor.

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.

HER2/HER3 heterodimers in prostate cancer

Another Piece of the p27Kip1 Puzzle

Resistance to EGFR-TKI Can Be Mediated through Multiple Signaling Pathways Converging upon Cap-Dependent Translation in EGFR-Wild Type NSCLC Manish R.

cMET Exon 14 Skipping: From the Structure to the Clinic

Volume 11, Issue 3, Pages (March 2007)

Figure 1 A schematic representation of the HER2 signalling pathway

Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas? Nicolas Girard, MD Journal of Thoracic.

A Sweet New Role for EGFR in Cancer

Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,

Schematic representation of main EGFR-TKIs resistance mechanisms.

Volume 29, Issue 3, Pages (March 2016)

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer Vassiliki Papadimitrakopoulou,

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung.

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Kostyantyn Krysan, PhD,

Hedgehog Signaling Pathway and Lung Cancer

A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin

Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non– Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI Akito Hata,

Xuewu Zhang, Jodi Gureasko, Kui Shen, Philip A. Cole, John Kuriyan

Vascular Endothelial Growth Factor (VEGF) Pathway

FGFR Signaling as a Target for Lung Cancer Therapy

The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor.

Matthew D. Hellmann, MD, Boris Reva, PhD, Helena Yu, MD, Valerie W

Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer Thomas Winder, Heinz–Josef.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench Kenichi Suda, MD, PhD, Paul A. Bunn,

V843I, a Lung Cancer Predisposing EGFR Mutation, Is Responsible for Resistance to EGFR Tyrosine Kinase Inhibitors Satsuki Matsushima, BSc, Kouki Ohtsuka,

Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung.

A Pilot Study of Preoperative Gefitinib for Early-Stage Lung Cancer to Assess Intratumor Drug Concentration and Pathways Mediating Primary Resistance

Erratum Journal of Thoracic Oncology

SRC and STAT Pathways Journal of Thoracic Oncology

Resisting Targeted Therapy: Fifty Ways to Leave Your EGFR

Yan Feng, MD, Praveena S. Thiagarajan, PhD, Patrick C. Ma, MD

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Benjamin Solomon, MBBS, PhD, Richard B. Pearson, PhD

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib Kenichi.

Insider Influence on ErbB Activity

Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD

Expression of Signaling Mediators Downstream of EGF-Receptor Predict Sensitivity to Small Molecule Inhibitors Directed Against the EGF-Receptor Pathway

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Daniel B. Costa, MD, PhD, Susan E. Jorge, PhD, Jason P

Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers Ryoichi Onozato, MD,

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer Charles M.

Mutant BRAF Melanomas—Dependence and Resistance

Friends with Benefits: Microenvironmental NRG1β and HGF Mediate HER2-Targeted Resistance in L-HER2+ and HER2E Breast Cancer Sarah B. Crist, Cyrus M.

Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib Tatsuya.

Two Rare Exon 21 EGFR Mutations in Patients Treated with Gefitinib

Successful targeting of ErbB2 receptors—is PTEN the key?

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival? Kenichi Suda, MD, Ryoichi Onozato, MD, Yasushi Yatabe, MD, Tetsuya Mitsudomi, MD Journal of Thoracic Oncology Volume 4, Issue 1, Pages 1-4 (January 2009) DOI: 10.1097/JTO.0b013e3181913c9f Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 The T790M mutation plays a double role in lung cancer cell survival. A, In the inactive conformation of the epidermal growth factor receptor (EGFR), the activation loop (A-loop) precludes the binding of peptide substrate. When the specific ligands bind the extracellular domain, EGFR dimerizes with other members of the ERBB family (ERBB3 in this scheme) in a tail-to-head fashion.35 The C lobe of the kinase domain plays a role analogous to that of cyclin in activated cyclin-dependent kinase (CDK)/cyclin complexes.35 The A-loop becomes extended to allow peptide substrate binding (active conformation), resulting in phosphorylation of tyrosine residues in regulatory domains. Phosphorylated tyrosine residues serve as docking sites for adaptor molecules that facilitate downstream signaling pathways, the most significant of which is the phosphatidylinositol-3-kinase (PI3K)-Akt pathway. B, EGFR mutation (L858R in this case) also promotes formation of active conformation. Gefitinib or erlotinib competitively inhibit binding of ATP to the EGFR kinase, resulting in inhibition of phosphorylation and downstream signaling. Gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.36C, When threonine 790 is substituted by methionine (T790M), the ATP affinity of the oncogenic L858R mutant is increased by more than an order of magnitude, leading to resistance to gefitinib/erlotinib.18 The T790M mutation also possesses enhanced phosphorylating activity, especially in combination with the L858R mutation. Several lines of evidence indicate that the T790M mutant is actually an oncogene. D, An irreversible EGFR-tyrosine kinase inhibitor (TKI) forms a covalent bond at cysteine 797 (C) even when the T790M mutation is present, and thus is able to inhibit the T790M mutant kinase. Journal of Thoracic Oncology 2009 4, 1-4DOI: (10.1097/JTO.0b013e3181913c9f) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions